广东肇庆星湖生物科技股份有限公司 独立董事 2024 年度述职报告 （刘艳清） 本人刘艳清，作为广东肇庆星湖生物科技股份有限公司 （以下简称"公司"或"上市公司"）独立董事，根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司 独立董事管理办法》等法律法规，以及《广东肇庆星湖生物 科技股份有限公司章程》等公司制度的规定和要求，本着独 立、客观、公正的原则，恪尽职守，勤勉尽责，积极出席相 关会议，认真审议各项议案，切实维护全体股东，尤其是中 小股东的合法权益。现将 2024 年度任职期间履行独立董事 职责情况汇报如下： 一、基本情况 （一）工作履历、任职情况以及专业背景 本人是肇庆学院食品与制药工程学院教授，2022 年 8 月 至今任公司独立董事。本人长期致力于天然产物提取、分离 与结构鉴定的教学与科研工作，积累了丰富的功能性食品与 小分子药物研发经验，具备作为公司的独立董事的专业资质 及能力，本人工作履历、专业背景以及兼职情况可详见公司披 露的 2024 年年度报告。 （二）是否存在影响独立性的情况说明 1 2.本人及直系亲属不在公司控股股东、实际控制人和其 附属企业任职，不存在与其存在重大业务 ...

广东肇庆星湖生物科技股份有限公司 委托理财管理制度 第一章 总则 第一条 为规范广东肇庆星湖生物科技股份有限公司（以下简称 "公司"）委托理财业务的管理，有效控制风险，提高资金使用效 率，维护公司及股东的利益，根据《中华人民共和国公司法》《中 华人民共和国证券法》《上海证券交易所股票上市规则》《上海证 券交易所上市公司自律监管指引第5号——交易与关联交易》等有关 法律、法规、规范性文件及《广东肇庆星湖生物科技股份有限公司 章程》（以下简称"《公司章程》"） 等的有关规定，结合公司实 际情况，特制定本制度。 第二条 本制度所称"委托理财"是指在国家政策、法律、法规 及上海证券交易所相关业务规则允许的情况下，公司在投资风险能有 效控制的前提下，以提高资金使用效率、增加现金收益为原则，委托 商业银行、证券公司、基金公司、信托公司等金融机构进行短期、低 风险投资理财的行为。 第三条 本制度适用于公司及合并报表范围内所有公司（以下 简称"子公司"）的委托理财管理。 第三章 委托理财的权限 第八条 公司对公司及子公司的年度理财计划进行审议，理财 计划中需明确委托理财的范围、种类、期限、额度、资金来源、预 期收益可行性以及 ...

广东肇庆星湖生物科技股份有限公司 独立董事 2024 年度述职报告 （刘衡） 本人刘衡，作为广东肇庆星湖生物科技股份有限公司 （以下简称"公司"或"上市公司"）的独立董事，根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司 独立董事管理办法》等法律法规，以及《广东肇庆星湖生物 科技股份有限公司章程》等公司制度的规定和要求，认真行 使法规所赋予的权利，忠实、勤勉地履行职责，充分发挥独 立董事在公司重大决策中的作用，促进公司规范运作，切实 维护全体股东尤其是中小股东的合法权益。现将 2024 年度 任职期间履行独立董事职责的情况汇报如下： 一、基本情况 （一）工作履历、任职情况以及专业背景 本人是中山大学管理学院教授，2022 年 8 月至今任公司 独立董事。本人多年从事工商管理、战略管理的教学和研究， 在管理专业领域积累了丰富的经验，拥有作为公司的独立董事 的专业资质及能力。本人工作履历、专业背景以及兼职情况可 详见公司披露的 2024 年年度报告。 （二）是否存在影响独立性的情况说明 经过自查，本人对自身的独立性情况进行以下说明: 1.本人及直系亲属、主要社会关系不在公司或公司附属 企业任职、且 ...

Financial Performance - The company's operating revenue for 2024 was approximately ¥17.33 billion, a slight decrease of 0.23% compared to ¥17.37 billion in 2023[23]. - Net profit attributable to shareholders increased by 39.12% year-on-year, reaching approximately ¥943.15 million, up from ¥677.95 million in 2023[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 57.07%, amounting to approximately ¥1.14 billion compared to ¥727.11 million in 2023[23]. - The basic earnings per share for 2024 was ¥0.5677, reflecting a 39.14% increase from ¥0.4080 in 2023[24]. - The weighted average return on equity increased by 2.91 percentage points to 12.30% in 2024, compared to 9.39% in 2023[24]. - The net cash flow from operating activities for 2024 was approximately ¥2.40 billion, an increase of 18.34% from ¥2.03 billion in 2023[23]. - The company's total assets at the end of 2024 were approximately ¥14.55 billion, a 1.15% increase from ¥14.38 billion at the end of 2023[23]. - The net assets attributable to shareholders increased by 4.16% to approximately ¥7.88 billion at the end of 2024, compared to ¥7.56 billion at the end of 2023[23]. - The total operating revenue for the reporting period was approximately CNY 16.71 billion, with a year-over-year decrease of 1.07%[86]. - The total operating cost was approximately CNY 13.98 billion, with a year-over-year decrease of 4.73%[86]. Dividend Policy - The company plans to distribute a cash dividend of 3.80 RMB per 10 shares, totaling 631.36 million RMB, which accounts for 66.94% of the net profit attributable to shareholders for the fiscal year 2024[6]. - The cumulative cash dividend over the last three accounting years was CNY 1.26 billion, with an average annual net profit of CNY 743.14 million, resulting in a cash dividend ratio of 169.92%[159]. - For 2024, the company plans to distribute CNY 3.80 per 10 shares, with a total cash dividend of CNY 631.36 million, representing 66.94% of the projected net profit attributable to shareholders[154]. Audit and Compliance - The company has received a standard unqualified audit report from Xinyong Zhonghe Accounting Firm, ensuring the accuracy and completeness of the financial report[5]. - The company has established a comprehensive internal control system that meets regulatory requirements and enhances decision-making efficiency[162]. - The internal control audit report issued by the auditing firm provided a standard unqualified opinion, confirming the effectiveness of the internal control system[164]. - The company has not faced any penalties from securities regulatory agencies in the past three years[135]. Research and Development - The company introduced 26 new invention patents and 14 utility model patents in 2024[36]. - Research and development expenses were 1.72 billion RMB, down 5.34% from the previous year, due to reduced consumption of materials and energy[51]. - The company is actively increasing R&D investment to overcome key technological challenges and accelerate new product development, aiming to enhance core competitiveness[119]. - The company is investing 200 million RMB in R&D for new technologies aimed at improving product efficiency[131]. Market Strategy and Expansion - The company is focusing on strategic integration across five areas: strategy, research and development, finance, business, and organization[35]. - The company is actively expanding its market share in core products like amino acids and nucleotides through precise marketing strategies[36]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[129]. - The company aims to become a global leader in feed additives and a comprehensive food flavor solution provider by 2025[113]. Environmental and Social Responsibility - The company invested CNY 309.84 million in environmental protection during the reporting period[165]. - The company has been recognized as a clean production enterprise in Guangdong Province since 2018, with multiple subsidiaries also receiving similar recognition[166]. - The company promotes green packaging and utilizes recyclable materials for product packaging, contributing to resource conservation[181]. - The company has published its 2024 ESG report, highlighting its commitment to social responsibility and sustainable development[186]. Risk Management - The company has established a risk management strategy for hedging operations, including strict control of futures positions and funding scale[104]. - The company is addressing financial risks by closely monitoring tax policy changes and utilizing financial derivatives to manage exchange rate risks[120]. - The company faces international trade risks due to potential changes in trade policies and tariffs, which could adversely affect export operations and overall performance[116]. - The company is exposed to raw material price volatility, particularly for corn and coal, which could impact overall gross margins and operational performance if prices fluctuate significantly[118]. Governance and Leadership - The company has established a robust governance structure to ensure compliance with legal regulations and effective decision-making processes[122]. - The company is led by a team with extensive experience in various sectors, including pharmaceuticals and management, which may enhance strategic decision-making[127]. - The company has a diverse board with independent directors, ensuring a range of perspectives in governance[126]. - The company has maintained a consistent board composition, with several members serving since 2023[126]. Operational Efficiency - The company has successfully implemented a financial shared service center to enhance accounting efficiency[35]. - The company emphasizes a circular economy approach, focusing on resource recycling and energy efficiency, which has led to significant reductions in pollutant emissions[46]. - The company achieved a significant increase in inventory levels for several product lines due to production exceeding sales in response to market demand fluctuations[59]. - The company has established a comprehensive quality management system, achieving certifications such as ISO9001 and FSSC22000, ensuring product quality meets global standards[5].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 4,039,271,975.90, a decrease of 3.82% compared to CNY 4,199,500,554.41 in the same period last year[4] - Net profit attributable to shareholders increased by 88.55% to CNY 474,173,136.28 from CNY 251,484,275.33 year-on-year[4] - The net profit after deducting non-recurring gains and losses rose by 81.61% to CNY 461,812,380.67 compared to CNY 254,289,592.09 in the previous year[4] - Basic earnings per share increased by 88.51% to CNY 0.2854 from CNY 0.1514 year-on-year[4] - Net profit for Q1 2025 reached CNY 476,619,833.40, an increase of 88.58% compared to CNY 253,490,763.01 in Q1 2024[20] - Earnings per share for Q1 2025 was CNY 0.2854, up from CNY 0.1514 in Q1 2024[21] - The company reported a total comprehensive income of CNY 526,220,762.08 for Q1 2025, compared to CNY 275,446,600.50 in Q1 2024[21] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 365,429,466.11, a significant increase from a negative CNY 194,797,528.20 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was CNY 365,429,466.11, a significant improvement from a negative cash flow of CNY -194,797,528.20 in Q1 2024[24] - The company's cash and cash equivalents amounted to ¥2.59 billion, up from ¥1.76 billion, indicating a significant increase of approximately 47.14%[14] - The total cash and cash equivalents at the end of the period amounted to 1,213,011,030.37, compared to 1,024,619,873.08 previously, indicating a positive cash position[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 16,397,995,359.12, up 12.70% from CNY 14,549,680,784.75 at the end of the previous year[5] - Total liabilities as of the reporting date were CNY 7,840,233,243.94, an increase from CNY 6,518,377,003.82 in the previous year[16] - The company reported a total equity of approximately ¥6.73 billion, up from ¥6.23 billion, which is an increase of about 8.03%[14] - Total current liabilities were reported at ¥4.66 billion, compared to ¥3.38 billion previously, indicating an increase of approximately 38.00%[15] Operational Efficiency - The company achieved a gross profit of CNY 907 million, an increase of CNY 267 million year-on-year, leading to a gross margin improvement[8] - Total operating costs for Q1 2025 were CNY 3,435,092,371.47, down 11.26% from CNY 3,871,156,784.69 in Q1 2024[19] - The decline in operating revenue was primarily due to a decrease in the sales prices of the company's main products compared to the previous year[8] Shareholder Information - Shareholders' equity attributable to the parent company increased by 6.65% to CNY 8,400,208,209.09 from CNY 7,876,583,459.20 year-on-year[5] - The number of shares held by the top shareholder, Guangdong Guangxin Holdings Group Co., Ltd., is 566,427,487, representing 34.09% of total shares[12] Investment Activities - The net cash flow from investing activities was -887,302,275.90, compared to -40,300,064.78 in the previous period, indicating a significant increase in cash outflow[25] - Cash outflow for investing activities was 1,137,886,341.81, significantly higher than 440,711,949.88 in the previous period, suggesting increased investment expenditures[25] - Cash inflow from investment activities was 250,584,065.91, down from 400,411,885.10, indicating a decrease in cash received from investments[25] - The cash paid for acquiring fixed assets, intangible assets, and other long-term assets was 268,944,585.06, compared to 40,711,949.88 previously, reflecting a substantial increase in capital expenditures[25] Financing Activities - Cash inflow from financing activities totaled 1,815,384,764.21, up from 1,450,000,000.00, reflecting a strong borrowing activity[25] - The net cash flow from financing activities was 560,153,059.80, contrasting with -80,017,288.13 in the prior period, showing improved financial health[25] - Cash received from loans was 1,815,075,860.63, compared to 1,450,000,000.00, indicating a rise in borrowing activities[25] - Cash paid for debt repayment was 1,231,501,098.50, slightly lower than 1,393,533,433.13 in the previous period, suggesting a reduction in debt servicing[25]

非经营性资金占用及其他关联资金往来的 广东肇庆星湖生物科技股份有限公司 2024 年度 专项说明 | 索引 | 项码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | | 胖系曲话' 字条所| 北京市东城区朝阳门北大街 8 号雷华大厦 A 牌 9 P No 8 Chaovanomen B Donachena District. Be 100027 P R China 关于广东肇庆星湖生物科技股份有限公司 2024 年度非经营性资金占用及其他关联资金往来的专项说明 除对星湖科技 2024年度财务报表执行审计,以及将本专项说明后附的汇总表所载 项目金额与我们审计星湖科技 2024年度财务报表时星湖科技提供的会计资料和经审计 的财务报表的相关内容进行核对外,我们没有对本专项说明后附的汇总表执行任何附加 程序。 XYZH/2025GZAA1B0192 广东肇庆星湖生物科技股份有限公司 广东肇庆星湖生物科技股份有限公司全体股东: 我们按照中国注册会计师审计准则审计了广东肇庆星湖生物科技股份有限公司(以 下简称星湖科技)2024年度财务报表,包括2024年 ...

证券代码：600866 证券简称：星湖科技 公告编号：临 2025-011 广东肇庆星湖生物科技股份有限公司 2024 年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整 性承担法律责任。 广东肇庆星湖生物科技股份有限公司（以下简称"公司"）根据 上海证券交易所《上市公司行业信息披露指引第十四号——食品制 造》的规定，现将公司 2024 年主要经营数据披露如下： 一、主营业务收入情况 单位：万元 币种：人民币 | 产品类别 | 本期主营业务收入 | | --- | --- | | 食品添加剂 | 424,776.89 | | 饲料添加剂 | 1,173,443.47 | | 生化原料药及制剂 | 12,914.36 | | 医药中间体 | 21,188.37 | | 有机肥料 | 38,705.13 | | 合计 | 1,671,028.22 | 二、销售渠道情况 单位：万元 币种：人民币 | | 销售渠道 | 本期主营业务收入 | | --- | --- | --- | | 直营 | | 1,671,028.22 | | ...

●本次会计政策变更系根据财政部发布的《企业会计准则解释第 18 号》（财会〔2024〕24 号）（以下简称"18 号解释"），进行的调整， 不会对公司当期的财务状况、经营成果和现金流量产生重大影响，不涉 及以前年度的追溯调整。 一、会计政策变更的概述 证券代码：600866 证券简称：星湖科技 公告编号：临 2025-018 广东肇庆星湖生物科技股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 重要内容提示： 2、本次会计政策变更后公司采用的会计政策 2024 年 12 月 6 日，财政部发布了《企业会计准则解释第 18 号》 （财会〔2024〕24 号）（以下简称"18 号解释"），18 号解释要求"关 于浮动收费法下作为基础项目持有的投资性房地产的后续计量""关于 不属于单项履约义务的保证类质量保证的会计处理"，解释内容自印发 之日起施行。根据 18 号解释要求，公司将对原会计政策进行相应变更， 并从规定的起始日开始执行。 本次会计政策变更前，公司执行财政部印发的《企业会计准则—— 基 ...

证券代码：600866 证券简称：星湖科技 公告编号：临 2025-015 广东肇庆星湖生物科技股份有限公司 关于使用闲置自有资金购买理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ● 投资种类：风险低、流动性好、稳健型的理财产品，包括但不限于一年 以内的短期银行理财产品、固定收益凭证产品及上海证券交易所、深圳证券交易 所挂牌交易的国债逆回购产品。 ● 投资金额：单日最高余额不超过人民币 380,000 万元。 ● 审议程序：广东肇庆星湖生物科技股份有限公司（以下简称"公司"） 第十一届董事会第十次会议审议通过了《关于使用闲置自有资金购买理财产品的 议案》，该事项在董事会审议范畴之内，无需提交股东大会审议。 一、投资情况概述 （一）投资目的 1 为提高资金使用效率，合理利用阶段性闲置资金，增加公司收益，公司及 全资子公司、控股子公司拟使用阶段性闲置自有资金购买风险低、流动性好、稳 健型的理财产品。 （二）投资金额 单日最高余额不超过人民币 380,000 万元，额度可以在 12 个月内滚动使用 ...

证券代码：600866 证券简称：星湖科技 公告编号：临 2025-017 广东肇庆星湖生物科技股份有限公司 关于补选非职工代表监事的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 广东肇庆星湖生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 20 日召开第十一届监事会第七次会议审议通过《关于补 选非职工代表监事的议案》，经公司控股股东广东省广新控股集团有 限公司推荐，同意提名罗怀生先生（简历详见附件）为公司第十一届 监事会非职工代表监事候选人。该事项尚需提交公司股东大会审议， 罗怀生先生的任期自公司股东大会审议通过之日起至第十一届监事 会届满之日止。 本次补选非职工代表监事经股东大会审议通过后，原股东代表监 事许荣丹女士正式离任，不再担任公司任何职务。公司及公司监事会 对其在任职期间所作出的贡献表示衷心感谢。 附件： 特此公告。 罗怀生先生简历 附件：罗怀生先生简历 罗怀生先生，中国国籍，无境外永久居留权，1979 年 9 月出生。 曾任广东省广新控股集团有限公司审计与监事管理部副部长。现任广 东省广 ...